Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA

Detalles Bibliográficos
Autores principales: Wehler, Elizabeth, Boytsov, Natalie, Nicolay, Claudia, Herrera-Restrepo, Oscar, Kowal, Stacey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081650/
https://www.ncbi.nlm.nih.gov/pubmed/31712980
http://dx.doi.org/10.1007/s40273-019-00857-7
_version_ 1783508214035251200
author Wehler, Elizabeth
Boytsov, Natalie
Nicolay, Claudia
Herrera-Restrepo, Oscar
Kowal, Stacey
author_facet Wehler, Elizabeth
Boytsov, Natalie
Nicolay, Claudia
Herrera-Restrepo, Oscar
Kowal, Stacey
author_sort Wehler, Elizabeth
collection PubMed
description
format Online
Article
Text
id pubmed-7081650
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70816502020-03-23 Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA Wehler, Elizabeth Boytsov, Natalie Nicolay, Claudia Herrera-Restrepo, Oscar Kowal, Stacey Pharmacoeconomics Correction Springer International Publishing 2019-11-12 2020 /pmc/articles/PMC7081650/ /pubmed/31712980 http://dx.doi.org/10.1007/s40273-019-00857-7 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Correction
Wehler, Elizabeth
Boytsov, Natalie
Nicolay, Claudia
Herrera-Restrepo, Oscar
Kowal, Stacey
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
title Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
title_full Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
title_fullStr Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
title_full_unstemmed Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
title_short Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
title_sort correction to: a budget impact and cost per additional responder analysis for baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to tumor necrosis factor inhibitors in the usa
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081650/
https://www.ncbi.nlm.nih.gov/pubmed/31712980
http://dx.doi.org/10.1007/s40273-019-00857-7
work_keys_str_mv AT wehlerelizabeth correctiontoabudgetimpactandcostperadditionalresponderanalysisforbaricitinibforthetreatmentofmoderatetosevererheumatoidarthritisinpatientswithaninadequateresponsetotumornecrosisfactorinhibitorsintheusa
AT boytsovnatalie correctiontoabudgetimpactandcostperadditionalresponderanalysisforbaricitinibforthetreatmentofmoderatetosevererheumatoidarthritisinpatientswithaninadequateresponsetotumornecrosisfactorinhibitorsintheusa
AT nicolayclaudia correctiontoabudgetimpactandcostperadditionalresponderanalysisforbaricitinibforthetreatmentofmoderatetosevererheumatoidarthritisinpatientswithaninadequateresponsetotumornecrosisfactorinhibitorsintheusa
AT herrerarestrepooscar correctiontoabudgetimpactandcostperadditionalresponderanalysisforbaricitinibforthetreatmentofmoderatetosevererheumatoidarthritisinpatientswithaninadequateresponsetotumornecrosisfactorinhibitorsintheusa
AT kowalstacey correctiontoabudgetimpactandcostperadditionalresponderanalysisforbaricitinibforthetreatmentofmoderatetosevererheumatoidarthritisinpatientswithaninadequateresponsetotumornecrosisfactorinhibitorsintheusa

Ejemplares similares